14 results about "Human feces" patented technology

The invention discloses a strain of Bacteroides ovatus L2 and application of the strain of Bacteroides ovatus L2 in a product for preventing and treating vomitoxin toxicity. The strain is preserved in Guangdong Microbiological Culture Collection Center, the preservation number is GDMCC.No: 67205, and the preservation date is November 4, 2025. The strain is separated and purified from a healthy adult excrement sample, has the characteristics of good acid resistance, cholate resistance, gastrointestinal fluid resistance and the like, and is free of hemolysis and good in safety. The strain can effectively relieve the toxic effect induced by vomitoxin, mainly inhibits inflammatory factors and promotes expression of intestinal barrier functional proteins, can be applied to products of microecologics for preventing and treating DON toxicity, and has a good application prospect.

Disclosed herein are methods for administering a dose of a microbiota recovery therapy composition by colonoscopy. The methods disclosed herein are useful for the treatment of diseases and / or conditions of the digestive tract, such as Clostridium difficile infection (GDI), including recurrent GDI, and other gastrointestinal disorders. The method can result in improved quality of life. These methods are capable of altering the gut microbiota composition and / or the gut metabolome composition. The microbiota recovery therapy composition comprises a fecal microbiota suspension comprising: a fecal microorganism derived from a human fecal sample, and a solution of polyethylene glycol and brine.

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

The invention provides a simulated excrement sample for radioactive bioassay and application of the simulated excrement sample. The simulated excrement sample comprises inorganic components and organic components. The simulated excrement sample is close to real human excrement in composition, physicochemical properties and biological activity, nuclides are uniformly distributed in the simulated excrement sample and can be stored for a long time, and a reliable research tool can be provided for radioactive bioassay, especially in the fields of drug research and development, environmental monitoring and the like.

The present application belongs to the technical field of microbial inoculants, and particularly relates to a Phocaediola doleeri, and further discloses a use of the Phocaediola doleeri in preparing a product for preventing and treating glycolipid metabolic disorder. A YG0564 strain is screened from healthy adult feces, and is identified as the Phocaediola doleeri and classified and named as Phocaediola doleeri. The Phocaediola doleeri strain YG0564 contains cholesteryl sulfatase, and can significantly reduce blood fat and blood sugar in vivo and in vitro, and can obviously prevent and treat obesity and glycolipid metabolic disorder.

The invention provides a method for simultaneously determining the contents of various short-chain fatty acids in human excrement, and innovatively develops an artificial excrement simulated blank matrix and a related detection system in order to solve the industrial problem that an effective blank matrix is lacked in excrement short-chain fatty acid (SCFAs) detection. The blank matrix is composed of a diluent, a microbial structure simulation agent and a fiber matrix skeleton, the problem of natural matrix deficiency is solved, and high-throughput, standardized and accurate quantitative analysis of the SCFAs in the excrement is achieved. A calibration curve is constructed on the basis of the matrix, synchronous and accurate quantification of the SCFAs in the excrement including acetic acid, propionic acid, butyric acid and the like is realized by combining a 3-NPH / EDC-pyridine derivatization LC-MS / MS technology, the recovery rate of the method is as high as 92.6%-111.2%, and the matrix effect deviation is stabilized to be smaller than or equal to + / -5%. The matched kit integrates the blank matrix, an SCFAs standard substance, a butyric acid-d7 internal standard and a derivatization reagent, and provides a standardized detection process. According to the achievement, the accuracy (RSD is less than or equal to 5%) of excrement SCFAs detection is remarkably improved, and the technical blank in the field is effectively filled.

The invention discloses humanized lactobacillus johnsonii MYR-117 and application thereof, the preservation number of the humanized lactobacillus johnsonii MYR-117 is GDMCC No: 65346, the humanized lactobacillus johnsonii MYR-117 is separated and identified from a faeces sample of a healthy person, and a mouse myelosuppression model is further combined to find that the lactobacillus johnsonii can resist myelosuppression induced by cyclophosphamide, so that the lactobacillus johnsonii MYR-117 can be used for resisting myelosuppression induced by cyclophosphamide; the levels of white blood cells, hemoglobin, platelets and red blood cells can be increased, bone marrow cell apoptosis is reduced, the thighbone marrow form is recovered, and the bone marrow hematopoietic capacity is Therefore, the compound can be used for preparing anti-myelosuppression drugs, leukocyte increasing drugs, erythrocyte increasing drugs, chemotherapy adjuvant therapy drugs and health-care products. Meanwhile, as the lactobacillus johnsonii is edible probiotics, the lactobacillus johnsonii can be used for preparing health-care food.

The present application relates to a kind of Bacteroides in lowering blood sugar. Specifically, the present application provides a kind of Bacteroides plebeius J2525 with the function of lowering blood sugar, which is a strain of gram-negative bacteria isolated and purified from human feces, which has been preserved in China General Microbiological Culture Collection Center (CGMCC) on April 25, 2025, and the preservation number is CGMCC NO.46398. The present application also provides the use of Bacteroides plebeius J2525 of the present application in the preparation of products for lowering blood sugar, improving glucose tolerance or improving insulin sensitivity. The present application shows that Bacteroides plebeius strain J2525 can be developed as a kind of probiotics with good blood sugar lowering effect, and has high reference value for the application of the strain in clinic.

The present disclosure provides freeze-dried compositions that include an extract of human feces and a flavoring agent, where the compositions, upon reconstitution with a liquid, have no objectionable odor and has no objectionable taste. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease. In some embodiments, the subject can be an individual with reduced ability to swallow, such as pill dysphagia, or an individual refractory to administration of a liquid having an objectionable odor or objectionable taste.

This invention discloses a method and application for preparing Renzhonghuang (a traditional Chinese medicine) from licorice using artificially synthesized bacterial cultures through fermentation. It belongs to the field of traditional Chinese medicine preparation technology. The method involves analyzing the dominant probiotic flora in healthy human fecal samples using metagenomic sequencing, screening out 15 representative intestinal probiotic strains, and constructing an artificially synthesized bacterial culture based on their relative abundance ratios in the natural gut. Licorice powder is mixed with a suspension of the artificially synthesized bacterial culture, and fermented at 37°C to prepare Renzhonghuang. The resulting Renzhonghuang is stable in quality and has high safety. Pharmacological experiments have confirmed that its anti-H1N1 influenza virus effect is superior to that of Renzhonghuang produced using traditional methods, significantly reducing viral load, inflammatory factor levels, and lung index in lung tissue, and improving lung pathological damage. This invention eliminates the unclean process of traditional cesspool fermentation, achieving standardized, controllable, and industrialized production of Renzhonghuang, and has significant clinical application value and market prospects.

The invention discloses Lactobacillus salivarius NCU-41 and application thereof, and belongs to the field of microbial medicines.The strain is a new strain which is screened from faeces of healthy people and has the activity of preventing and / or relieving Parkinson's disease, and the strain is gram-positive bacillus-free, has no hemolytic activity and no cytotoxicity, meets the safety standard of probiotics, and can be used for preparing probiotics for preventing and / or relieving Parkinson's disease. The lactobacillus salivarius NCU-41 can be applied for a long time through an oral preparation, so that side effects such as liver and kidney injury and gastrointestinal tract reaction caused by treating Parkinson's disease through chemical drugs are avoided, and a mechanism that the lactobacillus salivarius NCU-41 and the metabolite of the lactobacillus salivarius NCU-41 enhance the anti-oxidation defense capability in the brain by activating an AKT / Nrf2 signal channel is further researched and clarified.

The invention discloses a culture medium and a culture method for culturing human intestinal flora in vitro, every 1000g of the culture medium contains 5-20g of casein tryptone, 1-10g of beef extract, 1-10g of soybean oligosaccharide, 0.1-1g of monopotassium phosphate, 1-15g of sodium chloride, 0.5-5mg of hemin, 1-5g of cysteine hydrochloric acid, 0.5-2g of cholate, 20-100g of microcrystalline cellulose and 1-5g of agar powder, water is added to fix the volume to 1000mL, and the pH value is adjusted to 6.0-7.5. And after high-temperature steam sterilization, cooling to 40 DEG C, adding 0.5-5 / 1000 (V / V) serum, and uniformly mixing. The invention provides a culture medium and a culture method capable of culturing flora growth in human excrement twice through passage. In-vitro culture similar to intestinal flora characteristics of healthy donors is successfully realized, so that an ideal intestinal bacteria product is provided for intestinal bacteria transplantation treatment.

The present application belongs to the technical field of microbial inoculants, and particularly relates to a Bifidobacterium lactis, and further discloses a use of the Bifidobacterium lactis in preparation of an anti-obesity product and / or a weight loss product. A YG2013 strain is screened from healthy adult feces, and is identified as the Bifidobacterium lactis and classified as Bifidobacterium lactis. According to experimental identification, the Bifidobacterium lactis YG2013 strain can realize white adipose beige and activate brown adipose metabolism heat production through targeted regulation of tgr5 / Il-27, so as to achieve the effect of efficient weight loss, and has a good effect of treating weight loss and weight loss.

Disclosed herein are methods for administering a dose of a microbiota restoration therapy composition by colonoscopy. The methods disclosed herein are useful for treating diseases and / or conditions of the digestive tract, such as Clostridioides difficile infection (GDI), including recurrent GDI, and other gastrointestinal disorders. The method may result in improved quality of life. The methods may alter gut microbiota composition and / or gut metabolome composition. The microbiota restoration therapy composition comprises a fecal microbiota suspension comprising: fecal microbes derived from a human fecal sample, and a solution of polyethylene glycol and saline.